Udiliva is used to reduce cholesterol saturation in bile and promote the gradual dissolution of cholesterol gallstones. During treatment, Ursodeoxycholic Acid reduces cholesterol secretion into bile and increases bile acid secretion without reducing phospholipid secretion.
- Dissolution of gallstones: 8–12 mg/kg/day, given either as a single bedtime dose or in divided doses.
- Primary biliary cirrhosis: 10–15 mg/kg/day in 2–4 divided doses.
- Acute viral hepatitis: 600 mg/day.
- Alcoholic fatty liver: 300 mg/day.
- Primary sclerosing cholangitis: 25–30 mg/kg/day.
- Dissolution of gallstones and non-alcoholic steatohepatitis: 13–15 mg/kg/day.
This changes bile from a cholesterol-supersaturated state to a less saturated state, helping facilitate the gradual dissolution of cholesterol gallstones.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Ursodeoxycholic Acid is a naturally occurring bile acid used in the management of various hepatobiliary disorders. It primarily works by reducing cholesterol secretion into bile.
Its effects are achieved through several mechanisms, including reducing intestinal cholesterol absorption and suppressing hepatic cholesterol synthesis while not inhibiting bile acid synthesis.
As a result, Ursodeoxycholic Acid alters bile composition from supersaturated to unsaturated with respect to cholesterol. It also promotes the formation of liquid cholesterol crystal complexes, which facilitate the removal of cholesterol from the gallbladder into the intestine for elimination.
Ursodeoxycholic Acid may improve cholestatic liver diseases by:
Ursodeoxycholic Acid is well absorbed from the upper intestine. Peak serum concentrations are generally reached within 30–150 minutes, with an absorption rate of approximately 60–80%. After absorption, it enters the portal circulation and is taken up by the liver, where it is conjugated with glycine or taurine and subsequently secreted into the bile ducts.
Only small quantities appear in systemic circulation, and very small amounts are excreted in urine. The biological half-life of Ursodeoxycholic Acid ranges from approximately 3.5 to 5.8 days.
Udiliva may interact with medicines that affect bile cholesterol or reduce its absorption.
Ursodeoxycholic Acid has been used during pregnancy, including for the management of cholestasis of pregnancy, under medical supervision. Available clinical experience has not demonstrated evidence of harm to the fetus.
Pregnant or breastfeeding women should consult their doctor before using Udiliva. The decision to use the medicine should be based on the individual clinical condition and medical advice.
Udiliva should be used cautiously in patients with liver disease. Appropriate medical monitoring may be required during treatment.
Store below 25°C. Protect from light and moisture. Keep out of the reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.